Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17523865 | 1.00 | LMNA (0.45) | LMNAALDH1A1MEN1CYP3A4ALOX15 | |
| SCHEMBL17523947 | 0.98 | LMNA (0.48) | LMNAALDH1A1MEN1CYP3A4ALOX15 | |
| SCHEMBL17523949 | 0.98 | LMNA (0.48) | LMNAALDH1A1MEN1CYP3A4ALOX15 | |
| SCHEMBL17523805 | 0.96 | LMNA (0.40) | LMNAALDH1A1MEN1CYP3A4ALOX15 | |
| SCHEMBL17523804 | 0.96 | LMNA (0.40) | LMNAALDH1A1MEN1CYP3A4ALOX15 | |
| SCHEMBL25371761 | 0.87 | TSHR (0.35) | LMNAALDH1A1TSHRRIPK1 | |
| SCHEMBL17523871 | 0.85 | LMNA (0.46) | LMNAALDH1A1RIPK1 | |
| SCHEMBL17523869 | 0.85 | LMNA (0.46) | LMNAALDH1A1RIPK1 | |
| SCHEMBL17523867 | 0.83 | LMNA (0.68) | LMNAALDH1A1CYP3A4 | |
| SCHEMBL17523950 | 0.83 | LMNA (0.50) | LMNAALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | LMNA 3497/4885ALDH1A1 2376/4885MEN1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.